Dawaa Reference

infectious

Septic Arthritis (Emergency Referral)

Treatment options, dosing, cautions and Egyptian brands from the shipped Dawaa Reference card.

Evidence status

Checked against the sources named below

Sources6 sources

BSR guideline scope: Management of septic arthritis in adults with a hot swollen joint (Rheumatol Adv Pract 2025;9(3):rkaf058) · BSR/BHPR/BOA/RCGP/BSAC guideline for management of the hot swollen joint in adults (Coakley et al, Rheumatology 2006;45:1039-41) · Knee Arthrocentesis - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK470229/ · Septic Arthritis: Diagnosis and Treatment (Am Fam Physician 2021;104(6):589-597) · Egyptian National Drug Formulary - Antimicrobial 2023 (vancomycin monograph, p333) · Egyptian National Drug Formulary - Antimicrobial 2023 (ceftriaxone monograph, p255)

Verified against2 documents
  • Egyptian National Drug Formulary - Antimicrobial 2023 (vancomycin monograph, p333)
  • Egyptian National Drug Formulary - Antimicrobial 2023 (ceftriaxone monograph, p255)

Verified date2026-08

Presentation reference

Is it this?

Reference only, to read alongside your own examination.

Symptoms — what the patient reports (5)

  • Sudden onset of pain confined to one joint, with fever, is the classic presentation [fever]
  • A young sexually active adult with a shifting pattern of joint pain suggests gonococcal arthritis [joint pain]
  • In children, local joint symptoms may occur alone or together with systemic illness
  • A child refusing to move or bear weight on the joint is a key local complaint [refusing to use a limb]
  • Ill appearance with fussiness and poor appetite are systemic complaints in affected children [poor appetite]

Signs — what you find (5)

  • The knee is affected more often than any other joint, followed by hip, shoulder, and ankle
  • A joint effusion with limited motion and pain on palpation is typical on exam [joint swelling]
  • A single swollen joint points more toward staph infection, while multiple joints raise suspicion for gonococcus [joint swelling]
  • A draining sinus tract is typical when a prosthetic joint is infected
  • Skin lesions, tendon sheath inflammation, and non-erosive joint changes can accompany gonococcal infection [skin lesions]

Tests (8)

  • A joint fluid white cell count above 50,000 with over 90 percent neutrophils points to a bacterial cause
  • Growing an organism from the joint fluid confirms the diagnosis
  • A joint fluid cell count can be falsely low with leukopenia, an early infection, gonococcal disease, or a prosthesis in place
  • In an infected prosthetic joint, a fluid count near 1100 cells with 64 percent neutrophils is enough to suggest infection
  • Two blood culture sets should be drawn to check for bloodstream spread
  • A plain X-ray showing widened joint space or soft tissue bulging supports the diagnosis, but a normal film does not exclude it
  • MRI picks up early joint fluid and can show how far the infection has spread into surrounding tissue
  • A bone scan cannot tell infection apart from a sterile inflammatory process

If not this — what else fits (4)

  • Gout, pseudogout, and other crystal deposits can inflame a single joint the same way infection does
  • A joint fracture, meniscal tear, or retained foreign body can mimic an infected joint
  • Rheumatoid arthritis and the spondyloarthropathies belong on the differential for an inflamed joint
  • Bleeding into a joint from a clotting disorder or anticoagulant use can resemble septic arthritis

Scores

  • Kocher criteria — Septic arthritis, or transient synovitis of the hip?

SourceStatPearls "Septic Arthritis" - disease-level clinical article

Presentation findings are traced to the source above.

Rx: Empirical antistaphylococcal cover | Added gram-negative cover | Main treatment

EMPIRICAL ANTISTAPHYLOCOCCAL COVER

1

VANCOMYCIN

Empirical antistaphylococcal cover

1st line

Strength500 mg

Forminjection

Adult dose and duration

Intravenous. Where a loading dose is used the formulary gives 25 to 30 mg/kg, then 15 to 20 mg/kg every 8 to 12 hours at normal renal function, adjusted afterwards on measured blood levels. - About 2 weeks intravenously, then 1 to 2 weeks orally - 3 to 4 weeks in total, and 4 to 6 weeks where Pseudomonas is grown

Paediatric dose

10-15 mg/kg/dose

(The formulary prints no ordinary paediatric dose for vancomycin. It appears only as the stated baseline of the renal-adjustment table: those adjustments are based on intravenous doses of 10 mg/kg every 6 hours or 15 mg/kg every 8 hours. Both are per dose, not per day, and each figure is locked to its own interval: 10 mg/kg goes six-hourly and 15 mg/kg goes eight-hourly, which come to 40 and 45 mg/kg a day. They are not a range to pick from freely: pairing the higher amount with the shorter interval gives a daily total the formulary states nowhere. No paediatric ceiling is printed because the formulary states none - the dose is set by measured blood levels, not by a cap.)

Dose by weight
3kg30-45 mg/dose
4kg40-60 mg/dose
5kg50-75 mg/dose
6kg60-90 mg/dose
7kg70-105 mg/dose
8kg80-120 mg/dose
9kg90-135 mg/dose
10kg100-150 mg/dose
11kg110-165 mg/dose
12kg120-180 mg/dose
13kg130-195 mg/dose
14kg140-210 mg/dose
15kg150-225 mg/dose
16kg160-240 mg/dose
17kg170-255 mg/dose
18kg180-270 mg/dose
19kg190-285 mg/dose
20kg200-300 mg/dose
21kg210-315 mg/dose
22kg220-330 mg/dose
23kg230-345 mg/dose
24kg240-360 mg/dose
25kg250-375 mg/dose
26kg260-390 mg/dose
27kg270-405 mg/dose
28kg280-420 mg/dose
29kg290-435 mg/dose
30kg300-450 mg/dose
31kg310-465 mg/dose
32kg320-480 mg/dose
33kg330-495 mg/dose
34kg340-510 mg/dose
35kg350-525 mg/dose
36kg360-540 mg/dose
37kg370-555 mg/dose
38kg380-570 mg/dose
39kg390-585 mg/dose
40kg400-600 mg/dose
41kg410-615 mg/dose
42kg420-630 mg/dose
43kg430-645 mg/dose
44kg440-660 mg/dose
45kg450-675 mg/dose
46kg460-690 mg/dose
47kg470-705 mg/dose
48kg480-720 mg/dose
49kg490-735 mg/dose
50kg500-750 mg/dose
AWaRe

WATCH group - carries resistance cost. Egyptian EML 2025.

Dose source

Egyptian National Drug Formulary - Antimicrobial 2023 (vancomycin monograph, p333)

Why

The card's article states that empirical antibiotic coverage includes antistaphylococcal coverage - nafcillin, oxacillin or vancomycin - for all age and risk categories, and that empirical treatment of non-gonococcal septic arthritis usually involves intravenous vancomycin against gram-positive organisms, especially where MRSA is suspected on local data. It states no amount. The amounts here are the Egyptian formulary's, and the formulary states them only inside its renal-adjustment table: the first row of that table is normal renal function.

Cautions
  • NAFCILLIN AND OXACILLIN ARE NOT REGISTERED IN EGYPT. The article names all three; only vancomycin is on the Egyptian register, which is why it is the row.
  • THE DOSE IS SET BY BLOOD LEVELS, NOT BY THE NUMBER ABOVE. The formulary asks for initial dosing on actual body weight and for every subsequent dose to be adjusted on therapeutic monitoring, and for levels to be monitored in any degree of renal impairment. The figure printed is a starting point for a patient with normal kidneys.
  • THE KIDNEYS DECIDE THE INTERVAL, AND MOSTLY NOT THE DOSE. In the formulary's adult table the maintenance dose is 15 to 20 mg/kg both above a creatinine clearance of 90 and in the 50 to 90 band; what changes between them is the interval, 8 to 12 hours becoming 12 hours, and the loading dose, 25 to 30 mg/kg becoming 20 to 25 mg/kg. Only below a clearance of 50 does the maintenance dose itself fall, to 10 to 15 mg/kg every 24 hours. The paediatric table is separate and is keyed on GFR: 10 mg/kg per dose every 12 hours at a GFR of 30 to 50, every 18 to 24 hours at 10 to 29, and at under 10 a single 10 mg/kg dose redosed on measured levels.
  • DRAINING THE JOINT IS HALF THE TREATMENT. The article's regimen is antimicrobial therapy AND joint fluid drainage by arthrotomy, arthroscopy or daily needle aspiration, with the orthopaedic surgeon deciding which. Antibiotics alone are not the treatment.
  • ASPIRATE BEFORE THE FIRST DOSE WHERE THAT IS POSSIBLE. The article asks for empirical intravenous therapy to start promptly after joint aspiration is complete and cultures are taken - starting antibiotics first can make the culture unreadable.
  • THIS IS A HOSPITAL INFUSION, NOT A CLINIC DRUG. The regimen is printed so the GP knows what the patient is being sent for and can recognise it, not so it is started in the surgery. Referral comes first.
  • Do not give in hypersensitivity to vancomycin or any component of the formulation.
Egyptian brands
Egyptian brandManufacturerIndicative price
KEMPOVANCOM 500 MG VIALKAHIRA > MODERN OFFICE FOR IMPORT18.00 EGP
VANCOZIN 500 MG VIALEIMC > KOREA UNITED PHARMA38.00 EGP
VANCOMIX 500MG I.V. VIALSIGMA TEC79.00 EGP
VANCOGUT 500 MG PD. FOR I.V. INF. VIALARABCOMED95.00 EGP
VANCOLON 500MG I.V. VIALJULPHAR95.50 EGP
EDICIN 500 MG PD FOR I.V. INF. VIALGLOBAL PHARMACEUTICAL INDUSTRIES118.00 EGP
VANCOBACT 500 MG VIAL FOR I.V. INF.ARABCOMED > EGYPHARMA118.00 EGP
VANCOMYCINE VIATRIS 500 MG VIALVIANAX - GREECE > ONE PHARMA MEDICS142.00 EGP

ADDED GRAM-NEGATIVE COVER

2

CEFTRIAXONE

Added gram-negative cover

1st line

Strength1000 mg

Forminjection

Adult dose and duration

1 to 2 g intravenously or intramuscularly once daily, or the same total divided into two doses. Maximum 4 g daily. - Added to the antistaphylococcal cover for the same course; in gonococcal arthritis it is continued for 24 to 48 hours after improvement, then oral treatment for the rest

Paediatric dose

100 mg/kg/day [child max 2000 mg]

(The formulary gives two paediatric figures by severity, and the one printed is the severe-infection figure, because a joint that needs draining is not a mild infection: 100 mg/kg/day divided every 12 to 24 hours. Its mild-to-moderate figure is lower - 50 to 75 mg/kg once daily, maximum 1,000 mg/day. The formulary states three ceilings and they do not agree. The severe-infection dose line itself carries a maximum of 4,000 mg a day. Its Prescribing Limits section separately caps a child at 2 g daily for most infections and at 4 g daily for endocarditis or meningitis. The 2 g figure is the one applied above, because septic arthritis is neither endocarditis nor meningitis - which means the calculator stops rising at 20 kg, and a 30 kg child is shown 2,000 mg where 100 mg/kg would be 3,000 mg. The formulary supports the higher figure on its own dose line; the lower one is used here, and both are written out so the choice is visible rather than silent. A premature or term neonate is dosed separately at 50 mg/kg every 24 hours.)

Dose by weight
3kg300 mg/day
4kg400 mg/day
5kg500 mg/day
6kg600 mg/day
7kg700 mg/day
8kg800 mg/day
9kg900 mg/day
10kg1000 mg/day
11kg1100 mg/day
12kg1200 mg/day
13kg1300 mg/day
14kg1400 mg/day
15kg1500 mg/day
16kg1600 mg/day
17kg1700 mg/day
18kg1800 mg/day
19kg1900 mg/day
20kg2000 mg/day
21kg2000 mg/day (capped)
22kg2000 mg/day (capped)
23kg2000 mg/day (capped)
24kg2000 mg/day (capped)
25kg2000 mg/day (capped)
26kg2000 mg/day (capped)
27kg2000 mg/day (capped)
28kg2000 mg/day (capped)
29kg2000 mg/day (capped)
30kg2000 mg/day (capped)
31kg2000 mg/day (capped)
32kg2000 mg/day (capped)
33kg2000 mg/day (capped)
34kg2000 mg/day (capped)
35kg2000 mg/day (capped)
36kg2000 mg/day (capped)
37kg2000 mg/day (capped)
38kg2000 mg/day (capped)
39kg2000 mg/day (capped)
40kg2000 mg/day (capped)
41kg2000 mg/day (capped)
42kg2000 mg/day (capped)
43kg2000 mg/day (capped)
44kg2000 mg/day (capped)
45kg2000 mg/day (capped)
46kg2000 mg/day (capped)
47kg2000 mg/day (capped)
48kg2000 mg/day (capped)
49kg2000 mg/day (capped)
50kg2000 mg/day (capped)
AWaRe

WATCH group - carries resistance cost. Egyptian EML 2025.

Dose source

Egyptian National Drug Formulary - Antimicrobial 2023 (ceftriaxone monograph, p255)

Why

The card's article states that where the patient is immunocompromised, injects drugs, or the Gram stain is negative, a third-generation cephalosporin such as ceftriaxone, ceftazidime or cefotaxime should be added for gram-negative cover, and that gonococcal arthritis responds well to intravenous ceftriaxone. It states no amount. The amount is the Egyptian formulary's, whose ceftriaxone monograph names septic arthritis in its own indication list.

Cautions
  • THIS IS AN ADDITION FOR SELECTED PATIENTS, NOT THE ROUTINE SECOND DRUG. The article adds the cephalosporin where the patient is immunocompromised, injects drugs, or the Gram stain is negative, and for suspected Salmonella or gonococcal infection. Everyone gets the antistaphylococcal cover; not everyone gets this.
  • NOT IN A NEONATE ALONGSIDE INTRAVENOUS CALCIUM. The formulary contraindicates ceftriaxone with intravenous calcium-containing products in a neonate of 28 days or under, and in a jaundiced neonate - especially a premature one - because it displaces bilirubin from albumin. Cefotaxime is the third-generation cephalosporin to use there.
  • THE CULTURE DECIDES WHAT FOLLOWS. The article asks for blood and synovial fluid cultures and sensitivities to direct the prolonged course; this empirical choice lasts until they come back.
  • IF NOTHING IMPROVES IN 5 TO 6 DAYS, THE ANSWER IS NOT MORE ANTIBIOTIC. The article asks for the joint to be re-aspirated and for Lyme disease and other causes to be ruled out.
  • Do not give in hypersensitivity to ceftriaxone, any component, or another cephalosporin.
Egyptian brands
Egyptian brandManufacturerIndicative price
ZOXIDEL 1 GM PD. FOR I.M. INJ.RAMEDA > DELTA PHARMA22.00 EGP
CEFTRIAXONE SODIUM 1 GM I.M.VIAL (KAHIRA)KAHIRA29.00 EGP
ZOXIDEL 1 GM PD. FOR I.V. INJ.RAMEDA > DELTA PHARMA29.00 EGP
WINTRIAXONE 1 GM PD. FOR I.V INJ.SANOFI48.00 EGP
VOTRIAXONE 1 GM I.M VIALCHEMIPHARM56.00 EGP
OFRAMAX 1 GM I.M. VIALRAMEDA > SUN PHARMA EGYPT LIMITED71.00 EGP
TRIAXONE 1 GM I.M. VIALTABUK PHARMACEUTICAL MANUFACTURING COMPANY > TABUK PHARMA106.00 EGP
TRIAXONE 1 GM I.V VIALTABUK PHARMACEUTICAL MANUFACTURING COMPANY > TABUK PHARMA106.00 EGP

MAIN TREATMENT

3

REFERRAL & SAFETY-NETTING (NO DRUG THERAPY)

1st line
Adult dose and duration

Same-day referral to a hospital specialist who can aspirate the joint. Do NOT start an antibiotic in the clinic first. - Immediate same-day referral

Paediatric dose

The BSR guideline covers adults only; a separate BSR guideline for the hot, swollen or stiff joint in children and young people is still in development. Refer any child with a hot, swollen, painful joint, or a limp with fever, the same day. Do not start an antibiotic first.

Dose source

No dose - emergency referral pathway, no medicine given in primary care

Why

BSR 2006 grade B: the synovial fluid must be aspirated, Gram-stained and cultured prior to starting antibiotics. An antibiotic given before aspiration can sterilise the sample, so the organism is never identified and the six-week course cannot be targeted. BSR 2006 grade C: GPs should refer to a specialist within the hospital who has the expertise to aspirate the joint. Untreated or delayed, the joint is destroyed; the 2006 guideline reports a case fatality of 11%.

Cautions
  • DO NOT give an antibiotic before the joint is aspirated - it sterilises the sample and the organism is then never identified (BSR 2006, grade B).
  • TIME-CRITICAL: treat any acutely hot, swollen, painful joint as septic until aspiration proves otherwise, even when gout or a flare of known arthritis looks more likely.
  • Normal CRP, ESR or white cell count DO NOT exclude septic arthritis, and neither does the absence of fever (BSR 2025 scope).
  • A prosthetic or otherwise non-native joint must go to an orthopaedic surgeon, and must not be aspirated outside a sterile environment (BSR 2006 grade C; BSR 2025 scope).
  • Risk is higher with previous joint surgery, prosthetic joint, recent joint injection, rheumatoid arthritis, skin infection or ulcer, diabetes, and immunosuppression.
  • If the patient is also systemically unwell with signs of sepsis, the sepsis pathway takes priority - see Suspected Sepsis - and antibiotics should not be withheld waiting for aspiration.
  • In a sexually active adult consider gonococcal septic arthritis, which can present with migratory joint pain, tenosynovitis and a rash (Am Fam Physician 2021).

Prices are indicative (dataset snapshot 2026-06); verify with the pharmacy.